Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

ClinicalTrials.gov ID: NCT00654927

Public ClinicalTrials.gov record NCT00654927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Study identification

NCT ID: NCT00654927
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Acorda Therapeutics; Industry
Enrollment: 177 participants

Conditions and interventions

Conditions

Multiple Sclerosis

Interventions

Fampridine-SR b.i.d. (Twice Daily) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2003
Primary completion: Dec 31, 2010
Completion: Mar 31, 2011
Last update posted: Mar 1, 2012

2003 – 2011

United States locations

U.S. sites: 20
U.S. states: 16
U.S. cities: 20

Facility	City	State	ZIP	Site status
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center	Phoenix	Arizona	85013	—
USC, Keck School of Medicine Health Care Consultation Center	Los Angeles	California	90033	—
Shepherd Center	Atlanta	Georgia	30309	—
University of Chicago	Chicago	Illinois	60637	—
Maryland Center for MS	Baltimore	Maryland	21201	—
The Schapiro Center for MS	Golden Valley	Minnesota	55422	—
Washington University School of Medicine, Div. of Rehab/Neurology	St Louis	Missouri	63110	—
Gimbel MS Center at Holy Name Hospital	Teaneck	New Jersey	07666	—
University of Mexico, MIND Imaging Center	Albuquerque	New Mexico	87131	—
Maimonides MS Care Center	Brooklyn	New York	11219	—
Corinne Goldsmith Dickinson Center for MS	New York	New York	10029	—
University of Rochester	Rochester	New York	14642	—
SUNY Stony Brook	Stony Brook	New York	11794	—
CMC - Neuroscience & Spine Institute, Division of Neurology	Charlotte	North Carolina	28207	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Ohio State University MS Center	Columbus	Ohio	43221	—
Oregon Health & Science University, MS Center of Oregon, UHS-42	Portland	Oregon	97239	—
Thomas Jefferson University Physicians	Philadelphia	Pennsylvania	19107	—
University of Texas-Houston	Houston	Texas	77030	—
MS Center at Evergreen	Kirkland	Washington	98034	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00654927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 1, 2012 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00654927 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →